The role of peptide growth factors in epithelial ovarian cancer
- PMID: 2300354
The role of peptide growth factors in epithelial ovarian cancer
Abstract
We studied the effect of epidermal growth factor, platelet-derived growth factor, fibroblast growth factor, and transforming growth factor-beta on proliferation of four epithelial ovarian cancer cell lines (OVCA 420, OVCA 429, OVCA 432, and OVCA 433). Epidermal growth factor stimulated growth of OVCA 429 cells (P = .0001) and OVCA 433 cells (P = .0002). Platelet-derived growth factor did not stimulate growth of any of the cell lines. Fibroblast growth factor stimulated growth of OVCA 420 cells (P = .003). Transforming growth factor-beta inhibited growth of OVCA 420 cells (P = .0001), OVCA 432 cells (P = .003), and OVCA 433 cells (P = .004). To detect production of known growth factors by the cancer cell lines, we tested the effect of cancer cell-conditioned media on proliferation of cell lines known to respond to growth factors. Only media exposed to OVCA 433 cells were found to contain activity that mimicked one of the known growth factors (transforming growth factor-beta). These results suggest that individual ovarian cancers vary widely in their response to and production of known peptide growth factors. Finally, we found that OVCA 429-conditioned medium significantly inhibited proliferation of mitogen-stimulated lymphocytes (P less than .0001). The characteristics of this immunosuppressive factor were distinct from those of transforming growth factor-beta. Production of this factor by an immortalized cell line provides a unique opportunity to identify an immunosuppressive substance associated with ovarian cancer.
Similar articles
-
Regulation of apoptosis in normal and malignant ovarian epithelial cells by transforming growth factor beta.Cancer Res. 1995 Feb 15;55(4):944-8. Cancer Res. 1995. PMID: 7531618
-
Regulation of invasion of epithelial ovarian cancer by transforming growth factor-beta.Gynecol Oncol. 2001 Feb;80(2):245-53. doi: 10.1006/gyno.2000.6042. Gynecol Oncol. 2001. PMID: 11161867
-
Growth factors and cancer.Cancer Res. 1986 Mar;46(3):1015-29. Cancer Res. 1986. PMID: 3002607 Review.
-
Potential role of growth factors in ovarian cancer.Front Biosci. 1996 Dec 1;1:g14-9. Front Biosci. 1996. PMID: 9159261 Review.
-
Steroid and growth factor modulation of aromatase activity in MCF7 and T47D breast carcinoma cell lines.Cancer Res. 1992 Mar 15;52(6):1411-5. Cancer Res. 1992. PMID: 1311630
Cited by
-
Epidermal growth factor, oestrogen and progesterone receptor expression in primary ovarian cancer: correlation with clinical outcome and response to chemotherapy.Br J Cancer. 1995 Aug;72(2):361-6. doi: 10.1038/bjc.1995.339. Br J Cancer. 1995. PMID: 7640219 Free PMC article.
-
Growth stimulation of ovarian and extraovarian mesothelial cells by corpus luteum extract.In Vitro Cell Dev Biol Anim. 1993 Nov;29A(11):879-83. doi: 10.1007/BF02631367. In Vitro Cell Dev Biol Anim. 1993. PMID: 8167905
-
Production of insulin-like growth factor binding proteins by human ovarian carcinoma cells.J Cancer Res Clin Oncol. 1994;120(3):137-42. doi: 10.1007/BF01202191. J Cancer Res Clin Oncol. 1994. PMID: 7505272 Free PMC article.
-
Current Treatments and New Possible Complementary Therapies for Epithelial Ovarian Cancer.Biomedicines. 2021 Dec 31;10(1):77. doi: 10.3390/biomedicines10010077. Biomedicines. 2021. PMID: 35052757 Free PMC article. Review.
-
RhoB mediates antitumor synergy of combined ixabepilone and sunitinib in human ovarian serous cancer.Gynecol Oncol. 2012 Mar;124(3):589-97. doi: 10.1016/j.ygyno.2011.11.019. Epub 2011 Nov 22. Gynecol Oncol. 2012. PMID: 22115851 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical